Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
In this paper, we present a case of myxoid leiomyosarcoma development in a patient receiving tamoxifen for 3 years because of breast cancer. The myxoid leiomyosarcoma should be included in the differential diagnosis of any uterine tumor with a predominantly myxomatous composition. A review of the literature indicates that tamoxifen may increase not only the risk for endometrial cancer but also for uterine sarcoma, suggesting vigilance for uterine cancer in women who are being treated with this drug.
Botsis
Dimitris
D
Second Department of Obstetrics and Gynecology, University of Athens, Areteion University Hospital, Athens, Greece.
Koliopoulos
Carolina
C
Kondi-Pafitis
Agathi
A
Creatsas
George
G
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen